Cumulus Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Cumulus Oncology's estimated annual revenue is currently $4.5M per year.
- Cumulus Oncology's estimated revenue per employee is $155,000
Employee Data
- Cumulus Oncology has 29 Employees.
- Cumulus Oncology grew their employee count by 61% last year.
Cumulus Oncology Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 99 | -49% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 29 | -6% | N/A | N/A |
#10 | $9.6M | 62 | -7% | N/A | N/A |
What Is Cumulus Oncology?
Cumulus Oncology is developing anti-cancer therapies for clinical settings in areas of high unmet need, with the aim of developing improved outcomes for cancer patients. Cumulus has the backing of a successful entrepreneur in the oncology field, and is led by a team of senior professionals, each bringing a wealth of experience across a range of areas including licensing and business development, oncology drug discovery, pre-clinical and clinical development, who have delivered programs leading to the approval and commercial success of new treatments in oncology. We are keen to hear from organisations who are looking to partner late discovery and clinical stage oncology assets.
keywords:N/AN/A
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
61%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cumulus Oncology News
Drug discovery accelerator Cumulus Oncology has hired a chief scientific officer with invaluable skills and industry connections.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.3M | 29 | 12% | N/A |
#2 | $4.3M | 29 | -3% | N/A |
#3 | $5M | 29 | -28% | N/A |
#4 | $5M | 29 | -28% | N/A |
#5 | $5.1M | 29 | -3% | N/A |